Drug Trial Radar · NCT00674453
The Prevention Of Postmenopausal Osteoporosis With Lasofoxifene And Cytokine Evaluation
Last checked: Nov 19, 2026Latest source record: Aug 10, 2011 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
51
Actual
Start
Sep 2004
Primary completion
Not stated
Study completion Sep 2007
Sponsor
- Lead sponsor
- Ligand PharmaceuticalsIndustry
- Sponsor type
- Industry
- First posted
- May 7, 2008
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Basic science
- Who can join
- Female only, from 50 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The objective of the study is to demonstrate the effects that lasofoxifene has on serum markers of bone metabolism.
Conditions
- Bone Loss
Interventions
LasofoxifeneDrug
Oral tablet, 0.25 mg, daily, 2 years
PlaceboOther
Matching placebo tablet given once daily for 2 years
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in bone mineral density of the lumbar spine.Time frame: 2 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Pfizer Investigational Site
Sheffield, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.